# US 2014/0155594 A1 · [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155594 A1
- Document ID: US20140155594A1
- Status: Published application
- Kind: A1
- Application number: 13/869,374
- Filed: 2013-04-24
- Published: 2014-06-05
- Earliest claimed: 2007-10-10
- Assignees: Cancer Research Technology Limited
- Applicants: Cancer Research Technology Limited
- Inventors: Grégoire Alexandre Pavé; James Donald Firth; Lorna Stewart; Laurent Jean Martin Rigoreau; Emma Louise Stanway
- Web page: https://patentgrep.com/patent/US20140155594A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 35/00: Antineoplastic agents
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

## Claims

### Claim 1

A compound selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein:
—X═ is independently —CR6═ or —N═;
and wherein:
if —X═ is —CR6═, then:
—R5 is independently —R5A;
—R6 is independently —R6A;
—R7 is independently —R7A;
—R8 is independently —R8A; and
—W is independently —WA;
wherein:
—R5A is independently -Q5A;
—R6A is independently —H or -Q6A;
—R7A is independently —H or -Q7A;
—R8A is independently —H or -Q8A; and
—WA is independently —RWA1;
if —X═ is —N═, then:
—R5 is independently —R5B;
—R7 is independently —R7B;
—R8 is independently —R8B; and
—W is independently —WB;
wherein:
—R5B is independently -Q5B;
—R7B is independently —H or -Q7B;
—R8B is independently —H or -Q8B; and
—WB is independently —RWB1;
wherein:
—RWA1 is independently:
—R1A1, —R1A2, —R1A3, —R1A4, —R1A5, —R1A6, —R1A7, —R1A8,
-L1A-R1A4, -L1A-R1A5, -L1A-R1A6, -L1A-R1A7, or -L1A-R1A8;
—RWB1 is independently:
—R1A2, —R1A3, —R1A4, —R1A5, —R1A6, —R1A7, —R1A8,
-L1A-R1A4, -L1A-R1A5, -L1A-R1A7, or -L1A-R1A8;
wherein:
each —R1A1 is independently saturated aliphatic C1-6alkyl;
each —R1A2 is independently aliphatic C2-6alkenyl;
each —R1A3 is independently aliphatic C2-6alkynyl;
each —R1A4 is independently saturated C3-6cycloalkyl;
each —R1A5 is independently C3-6cycloalkenyl;
each —R1A6 is independently non-aromatic C3-8heterocyclyl;
each —R1A7 is independently C6-10carboaryl;
each —R1A8 is independently C5-10heteroaryl;
each -L1A- is independently saturated aliphatic C1-3alkylene;
wherein:
each —R1A4, —R1A5, —R1A6, —R1A7, and —R1A8 is optionally substituted, for example, with one or more substituents —R1B1 and/or one or more substituents —R1B2, and
each —R1A1, —R1A2, —R1A3, and -L1A- is optionally substituted, for example, with one or more substituents —R1B2,
wherein:
each —R1B1 is independently:
—R1D1. —R1D2, —R1D3, —R1D4, —R1D5, —R1D6, —R1D7, —R1D8,
-L1D-R1D4, -L1D-R1D5, -L1D-R1D6, -L1D-R1D7, or -L1D-R1D8;
each —R1B2 is independently:
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L1C-OH, —O-L1C-OH,
—OR1C1, -L1C-OR1C1, —O-L1C-OR1C1,
—SH, —SR1C1,
—CN,
—NO2,
—NH2, —NHR1C1, —NR1C12, —NR1C2R1C3,
-L1C-NH2, -L1C-NHR1C1, -L1C-NR1C12, -L1C-NR1C2R1C3,
—O-L1C-NH2, —O-L1C-NHR1C1, —O-L1C-NR1C12, —O-L1C-NR1C2R1C3,
—C(═O)OH, —C(═O)OR1C1,
—C(═O)R1C1,
—C(═O)NH2, —C(═O)NHR1C1, —C(═O)NR1C12, —C(═O)NR1C2R1C3,
—NHC(═O)R1C1, —NR1C1C(═O)R1C1,
—NHC(═O)OR1C1, —NR1C1C(═O)OR1C1,
—OC(═O)NH2, —OC(═O)NHR1C1, —OC(═O)NR1C12, —OC(═O)NR1C2R1C3,
—NHC(═O)NH2, —NHC(═O)NHR1C1,
—NHC(═O)NR1C12, —NHC(═O)NR1C2R1C3,
—NR1C1C(═O)NH2, —NR1C1C(═O)NHR1C1,
—NR1C1C(═O)NR1C12, —NR1C1C(═O)NR1C2R1C3,
—NHS(═O)2R1C1, —NR1C1S(═O)2R1C1,
—S(═O)2NH2, —S(═O)2NHR1C1, —S(═O)2NR1C12, —S(═O)2NR1C2R1C3,
—S(═O)R1C1, —S(═O)2R1C1, —OS(═O)2R1C1, or —S(═O)2OR1C1;
wherein:
each -L1C- is independently saturated aliphatic C1-5alkylene;
in each group —NR1C2R1C3, R1C2 and R1C3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N or O;
each —R1C1 is independently:
—R1D1, —R1D2, —R1D3, —R1D4, —R1D5, —R1D6, —R1D7, —R1D8,
-L1D-R1D4, -L1D-R1D5, -L1D-R1D6, -L1D-R1D7, or -L1D-R1D8,
each —R1D1 is independently saturated aliphatic C1-6alkyl;
each —R1D2 is independently aliphatic C2-6alkenyl;
each —R1D3 is independently aliphatic C2-6alkynyl;
each —R1D4 is independently saturated C3-6cycloalkyl;
each —R1D5 is independently C3-6cycloalkenyl;
each —R1D6 is independently non-aromatic C3-8heterocyclyl;
each —R1D7 is independently C6-10carboaryl;
each —R1D8 is independently C5-10heteroaryl;
each -L1D- is independently saturated aliphatic C1-3alkylene;
wherein:
each —R1D4, —R1D5, —R1D6, —R1D7, and —R1D8 is optionally substituted, for example, with one or more substituents —R1E1 and/or one or more substituents —R1E2,
each —R1D1, —R1D2, —R1D3, and -L1D- is optionally substituted, for example, with one or more substituents —R1E2, and
wherein:
each —R1E1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each —R1E2 is independently:
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L1F-OH, —O-L1F-OH,
—OR1F1, -L1F-OR1F1, —O-L1F-OR1F1,
—SH, —SR1F1,
—CN,
—NO2,
—NH2, —NHR1F1, —NR1F12, NR1F2R1F3,
-L1F-NH2, -L1F-NHR1F1, -L1F-NR1F12, -L1F-NR1F2R1R3,
—C(═O)OH, —C(═O)OR1F1,
—C(═O)NH2, —C(═O)NHR1F1, C(═O)NR1F12, or —C(═O)NR1F2R1F3;
wherein:
each —R1F1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each -L1F- is independently saturated aliphatic C1-5alkylene; and
in each group —NR1F2R1F3, R1F2 and R1F3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N or O;
-Q5A is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
-L2C-OR2C1, —O-L2C-OR2C1,
—O—R2D4, —O—R2D6, —O—R2D7, —O—R2D8,
—O-L2D-R2D4, —O—R2D6, —O—R2D7, —O—R2D8,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L-NR2C—NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
-Q8A is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
-L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
-Q5B is independently:
—R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R2A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
—OR2C1, -L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C2,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
-Q8B is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
—OR2C1, -L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
each of -Q6A, -Q7A, and -Q7B is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
—OR2C1, L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
wherein:
each —R2A1 is independently saturated aliphatic C1-6alkyl;
each —R2A2 is independently aliphatic C2-6alkenyl;
each —R2A3 is independently aliphatic C2-6alkynyl;
each —R2A4 is independently saturated C3-6cycloalkyl;
each —R2A5 is independently C3-6cycloalkenyl;
each —R2A6 is independently non-aromatic C3-8heterocyclyl;
each —R2A7 is independently C6-10carboaryl;
each —R2A8 is independently C5-10heteroaryl;
each -L2A- is independently saturated aliphatic C1-3alkylene;
wherein:
each —R2A4, —R2A5, —R2A6, —R2A7, and —R2A8 is optionally substituted, for example, with one or more substituents —R2B1 and/or one or more substituents —R2B2, and
each —R2A1, —R2A2, —R2A3, and -L2A- is optionally substituted, for example, with one or more substituents —R2B2,
wherein:
each —R2B1 is independently:
—R2D1, —R2D2, —R2D3, —R2D4, —R2D5, —R2D6, —R2D7, —R2D8,
-L2D-R2D4, -L2D-R2D5, -L2D-R2D6, -L2D-R2D7, or -L2D-R2D8;
each —R2B2 is independently:
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
—OR2C1, -L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR2C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR2C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
wherein:
each -L2C- is independently saturated aliphatic C1-5alkylene;
in each group —NR2C2R2C3, R2C2 and R2C3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N or O;
each —R2C1 is independently:
—R2D1, —R2D2, —R2D3, —R2D4, —R2D5, —R2D6, —R2D7, —R2D8,
-L2D-R2D4, -L2D-R2D5, -L2D-R2D6, -L2D-R2D7, or -L2D-R2D8;
each —R2D1 is independently saturated aliphatic C1-6alkyl;
each —R2D2 is independently aliphatic C2-6alkenyl;
each —R2D3 is independently aliphatic C2-6alkynyl;
each —R2D4 is independently saturated C3-6cycloalkyl;
each —R2D5 is independently C3-6cycloalkenyl;
each —R2D6 is independently non-aromatic C3-8heterocyclyl;
each —R2D7 is independently C6-10carboaryl;
each —R2D8 is independently C5-10heteroaryl;
each -L2D- is independently saturated aliphatic C1-3alkylene;
wherein:
each —R2D4, —R2D5, —R2D6, —R2D7, and —R2D8 is optionally substituted, for example, with one or more substituents —R2E1 and/or one or more substituents —R2E2,
each —R2D1, —R2D2, —R2D3, and -L2D- is optionally substituted, for example, with one or more substituents —R2E2, and
wherein:
each —R2E1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each —R2E2 is independently:
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2F-OH, —O-L2F-OH,
—OR2F1, -L2F-OR2F1, —O-L2F-OR2F1,
—SH, —SR2F1,
—CN,
—NO2,
—NH2, —NHR2F1, —NR2F12, —NR2F2R2F3,
-L2F-NH2, -L2F-NHR2F1, -L2F-NR2F12, -L2F-NR2F2R2F3,
—C(═O)OH, —C(═O)OR2F1,
—C(═O)NH2, —C(═O)NHR2F1, —C(═O)NR2F12, or —C(═O)NR2F2R2F3;
wherein:
each —R2F1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each -L2F- is independently saturated aliphatic C1-5alkylene; and
in each group —NR2F2R2F3, R2F2 and R2F3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N or O.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein:
—X═ is independently —CR6═;
—R5 is independently —R5A;
—R6 is independently —R6A;
—R7 is independently —R7A;
—R8 is independently —R8A;
—W is independently —WA; and
—WA is independently —RWA1.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein —R6A, if present, is independently —H.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein —R6A, if present, is independently -Q6A.

### Claim 5 (depends on 2)

A compound according to claim 2, wherein —R7A is independently —H.

### Claim 6 (depends on 2)

A compound according to claim 2, wherein —R7A is independently -Q7A.

### Claim 7 (depends on 2)

A compound according to claim 2, wherein —R8A is independently —H.

### Claim 8 (depends on 2)

A compound according to claim 2, wherein —R8A is independently -Q8A.

### Claim at position 9

9-13. (canceled)

### Claim 14 (depends on 2)

A compound according to claim 2, wherein —RWA1, if present, is independently:
—R1A1, —R1A4, —R1A6, —R1A7, —R1A8,
-L1A-R1A4, -L1A-R1A6, -L1A-R1A7, or -L1A-R1A8.

### Claim at position 11

15-21. (canceled)

### Claim 22 (depends on 2)

A compound according to claim 2, wherein —RWA1, if present, is independently —R1A7 or —R1A8.

### Claim at position 13

23-24. (canceled)

### Claim 25 (depends on 2)

A compound according to claim 2, wherein —RWB1, if present, is independently:
—R1A4, —R1A6, —R1A7, —R1A8,
-L1A-R1A4, -L1A-R1A7, or -L1A-R1A8.

### Claim at position 15

26-31. (canceled)

### Claim 32 (depends on 2)

A compound according to claim 2, wherein —RWB1, if present, is independently —R1A7 or —R1A8.

### Claim at position 17

33-34. (canceled)

### Claim 35

A compound selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein:
—X═ is independently —CR6═ or —N═;
and wherein:
if —X═ is —CR6═, then:
—R5 is independently —R5A;
—R6 is independently —R6A;
—R7 is independently —R7A;
—R8 is independently —R8A; and
—W is independently —WA;
wherein:
—R5A is independently -Q5A;
—R6A is independently —H or -Q6A;
—R7A is independently —H or -Q7A;
—R8A is independently —H or -Q8A; and
—WA is independently —C(═O)RWA2;
if —X═ is —N═, then:
—R5 is independently —R5B;
—R7 is independently —R7B;
—R8 is independently —R8B; and
—W is independently —WB;
wherein:
—R5B is independently -Q5B;
—R7B is independently —H or -Q7B;
—R8B is independently —H or -Q8B; and
—WB is independently —C(═O)RWB2;
wherein:
—RWA2 is independently:
—R1A1, —R1A2, —R1A3, —R1A4, —R1A5, —R1A6, —R1A7, —R1A8,
-L1A-R1A4, -L1A-R1A5, -L1A-R1A6, -L1A-R1A7, or -L1A-R1A8;
—RWB2 is independently:
—R1A2, —R1A3, —R1A4, —R1A5, —R1A6, —R1A7, —R1A8,
-L1A-R1A4, -L1A-R1A5, -L1A-R1A6, -L1A-R1A7, or -L1A-R1A8;
wherein:
each —R1A1 is independently saturated aliphatic C1-6alkyl;
each —R1A2 is independently aliphatic C2-6alkenyl;
each —R1A3 is independently aliphatic C2-6alkynyl;
each —R1A4 is independently saturated C3-6cycloalkyl;
each —R1A5 is independently C3-6cycloalkenyl;
each —R1A6 is independently non-aromatic C3-8heterocyclyl;
each —R1A7 is independently C6-10carboaryl;
each —R1A8 is independently C5-10heteroaryl;
each -L1A- is independently saturated aliphatic C1-3alkylene;
wherein:
each —R1A4, —R1A5, —R1A6, —R1A7, and —R1A8 is optionally substituted, for example, with one or more substituents —R1B1 and/or one or more substituents —R1B2, and
each —R1A1, —R1A2, —R1A3, and -L1A- is optionally substituted, for example, with one or more substituents —R1B2,
wherein:
each —R1B1 is independently:
—R1A1, —R1D2, —R1D3, —R1D5, —R1D6, —R1D7, —R1D8,
-L1D-R1D4, -L1D-R1D5, -L1D-R1D6, -L1D-R1D7, or -L1D-R1D8,
each —R1B2 is independently:
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L1C-OH, —O-L1C-OH,
—OR1C1, -L1C-OR1C1, —O-L1C-OR1C1,
—SH, —SR1C1,
—CN,
—NO2,
—NH2, —NHR1C1, —NR1C12, —NR1C2R1C3,
-L1C-NH2, L1C-NHR1C1, -L1C-NR1C12, -L1C-NR1C2R1C3,
—O-L1C-NH2, —O-L1C-NHR1C1, —O-L1C-NR1C12, —O-L1C-NR1C2R1C3,
—C(═O)OH, —C(═O)OR1C1,
—C(═O)R1C1,
—C(═O)NH2, —C(═O)NHR1C1, —C(═O)NR1C12, —C(═O)NR1C2R1C3,
—NHC(═O)R1C1, —NR1C1C(═O)R1C1,
—NHC(═O)OR1C1, —NR1C1C(═O)OR1C1,
—OC(═O)NH2, —OC(═O)NHR1C1, —OC(═O)NR1C12, —OC(═O)NR1C2R1C3,
—NHC(═O)NH2, —NHC(═O)NHR1C1,
—NHC(═O)NR1C12, —NHC(═O)NR1C2R1C3,
—NR1C1C(═O)NH2, —NR1C1C(═O)NHR1C1,
—NR1C1C(═O)NR1C12, —NR1C1C(═O)NR1C2R1C3,
—NHS(═O)2R1C1, —NR1C1S(═O)2R1C1,
—S(═O)2NH2, —S(═O)2NHR1C1, —S(═O)2NR1C12, —S(═O)2NR1C2R1C3,
—S(═O)R1C1, —S(═O)2R1C1, —OS(═O)2R1C1, or —S(═O)2OR1C1;
wherein:
each -L1C- is independently saturated aliphatic C1-5alkylene;
in each group —NR1C2R1C3, R1C2 and R1C3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N or O;
each —R1C1 is independently:
—R1D1, —R1D2, —R1D3, —R1D4, —R1D5, —R1D6, —R1D7, —R1D8,
-L1D-R1D4, -L1D-R1D5, -L1D-R1D6, -L1D-R1D7, or -L1D-R1D8;
each —R1D1 is independently saturated aliphatic C1-6alkyl;
each —R1D2 is independently aliphatic C2-6alkenyl;
each —R1D3 is independently aliphatic C2-6alkynyl;
each —R1D4 is independently saturated C3-6cycloalkyl;
each —R1D5 is independently C3-6cycloalkenyl;
each —R1D6 is independently non-aromatic C3-8heterocyclyl;
each —R1D7 is independently C6-10carboaryl;
each —R1D8 is independently C5-10heteroaryl;
each -L1D- is independently saturated aliphatic C1-3alkylene;
wherein:
each —R1D4, —R1D5, —R1D6, —R1D7, and —R1D8 is optionally substituted, for example, with one or more substituents —R1E1 and/or one or more substituents —R1E2,
each —R1D1, R1D2, —R1D3, and -L1D- is optionally substituted, for example, with one or more substituents —R1E2, and
wherein:
each —R1E1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each —R1E2 is independently:
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L1F-OH, —O-L1F-OH,
OR1F1, L1F-OR1F1, —O-L1F-OR1F1,
—SH, —SR1F1,
—CN,
—NO2,
—NH2, —NHR1F1, —NR1D12, —NR1F2R1F3,
-L1F-NH2, -L1F-NHR1F1, -L1F-NR1F12, -L1F-NR1F2R1F3,
—C(═O)OH, —C(═O)OR1F1,
—C(═O)NH2, —C(═O)NHR1F1, —C(═O)NR1F12, or —C(═O)NR1F2R1F3;
wherein:
each —R1F1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each -L1F- is independently saturated aliphatic C1-5alkylene; and
in each group —NR1F2R1F3, R1F2 and R1F3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N or O;
-Q5A is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
-L2C-OR2C1, —O-L2C-OR2C1,
—O—R2D4, —O—R2D6, —O—R2D7, —O—R2D8,
—O-L2D-R2D4, —O-L2D-R2D6, —O-L2D-R2D7, —O-L2D-R2D8,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, —O-L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
-Q8A is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
-L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C1R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NHR2C1R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
-Q5B is independently:
—R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
—OR2C1, -L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
-Q8B is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
—OR2C1, -L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
each of -Q6A, -Q7A, and -Q7B is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
—OR2C1, -L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, -L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR1C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
wherein:
each —R2A1 is independently saturated aliphatic C1-6alkyl;
each —R2A2 is independently aliphatic C2-6alkenyl;
each —R2A3 is independently aliphatic C2-6alkynyl;
each —R2A4 is independently saturated C3-6cycloalkyl;
each —R2A5 is independently C3-6cycloalkenyl;
each —R2A6 is independently non-aromatic C3-8heterocyclyl;
each —R2A7 is independently C6-10carboaryl;
each —R2A8 is independently C5-10heteroaryl;
each -L2A- is independently saturated aliphatic C1-3alkylene;
wherein:
each —R2A4, —R2A5, —R2A6, —R2A7, and —R2A8 is optionally substituted, for example, with one or more substituents —R2B1 and/or one or more substituents —R2B2, and
each —R2A1, —R2A2, R2A3, and -L2A- is optionally substituted, for example, with one or more substituents —R2B2,
wherein:
each —R2B1 is independently:
—R2D1, —R2D2, —R2D3, —R2D4, —R2D5, —R2D6, —R2D7, —R2D8,
-L2D-R2D4, -L2D-R2D5, -L2D-R2D6, -L2D-R2D7, or -L2D-R2D8;
each —R2B2 is independently:
—F, —Cl, —Br, —I,
—CF3, —OCF3,
—OH, -L2C-OH, —O-L2C-OH,
—OR2C1, -L2C-OR2C1, —O-L2C-OR2C1,
—SH, —SR2C1,
—CN,
—NO2,
—NH2, —NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OH, —C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)OR2C1, —NR2C1C(═O)OR2C1,
—OC(═O)NH2, —OC(═O)NHR2C1, —OC(═O)NR2C12, —OC(═O)NR2C2R2C3,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR2C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR2C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, —S(═O)2R2C1, —OS(═O)2R2C1, or —S(═O)2OR2C1;
wherein:
each -L2C- is independently saturated aliphatic C1-5alkylene;
in each group —NR2C2R2C3, R2C2 and R2C3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N or O;
each —R2C1 is independently:
—R2D1, —R2D2, —R2D3, —R2D4, —R2D5, —R2D6, —R2D7, —R2D8,
-L2D-R2D4, -L2D-R2D5, -L2D-R2D6, -L2D-R2D7, or -L2D-R2D8;
each —R2D1 is independently saturated aliphatic C1-6alkyl;
each —R2D2 is independently aliphatic C2-6alkenyl;
each —R2D3 is independently aliphatic C2-6alkynyl;
each —R2D4 is independently saturated C3-6cycloalkyl;
each —R2D5 is independently C3-6cycloalkenyl;
each —R2D6 is independently non-aromatic C3-8heterocyclyl;
each —R2D7 is independently C6-10carboaryl;
each —R2D8 is independently C5-10heteroaryl;
each -L2D- is independently saturated aliphatic C1-3alkylene;
wherein:
each —R2D4, —R2D5, —R2D6, —R2D7, and —R2D8 is optionally substituted, for example, with one or more substituents —R2E1 and/or one or more substituents —R2E2,
each —R2D1, —R2D2, —R2D3, and -L2D- is optionally substituted, for example, with one or more substituents —R2E2, and
wherein:
each —R2E1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each —R2E2 is independently:
—F, —Cl, —Br, —I,
CF3, —OCF3,
—OH, -L2F-OH, —O-L2F-OH,
—OR2F1, -L2F-OR2F1, —O-L2F-OR2F1,
—SH, —SR2F1,
—CN,
—NO2,
—NH2, —NHR2F1, —NR2F12, —NR2F2R2F3,
-L2F-NH2, -L2F-NHR2F1, -L2F-NR2F12, -L2F-NR2F2R2F3,
—C(═O)OH, —C(═O)OR2F1,
—C(═O)NH2, —C(═O)NHR2F1, —C(═O)NR2F12, or —C(═O)NR2F2R2F3;
wherein:
each —R2F1 is independently saturated aliphatic C1-4alkyl, phenyl, or benzyl;
each -L2F- is independently saturated aliphatic C1-5alkylene; and
in each group —NR2F2R2F3, R2F2 and R2F3, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteroatoms is independently N or O;
with the proviso that the compound is not a compound selected from the following compounds:
Cyclopropanecarboxylic acid (5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-amide (PP-001) (WW-001);
Cyclopropanecarboxylic acid [5-(3-acetylamino-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amide (PP-002) (WW-002);
Cyclopropanecarboxylic acid {5-[4-(4-methyl-piperazin-1-yl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl}-amide (PP-003) (WW-003);
Cyclopropanecarboxylic acid [5-(3-chloro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-004) (WW-004);
Cyclopropanecarboxylic acid [5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-005) (WW-005);
Cyclopropanecarboxylic acid [5-(6-methoxy-pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amide (PP-006) (WW-006);
Cyclopropanecarboxylic acid [5-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-007) (WW-007);
Cyclopropanecarboxylic acid [5-(4-hydroxy-3,5-dimethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-008) (WW-008);
4-[2-(Cyclopropanecarbonyl-amino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl]-N-(2-dimethylamino-ethyl)-benzamide (PP-009) (WW-009);
Cyclopropanecarboxylic acid [5-(2,4-dimethoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amide (PP-010) (WW-010);
Cyclopropanecarboxylic acid [5-(3-methanesulfonylamino-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-011) (WW-011);
Cyclopropanecarboxylic acid [5-(2-dimethylamino-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-012);
Cyclopropanecarboxylic acid [5-(3-chloro-4-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-013);
Cyclopropanecarboxylic acid [5-(3-trifluoromethoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-014);
Cyclopropanecarboxylic acid [5-((E)-styryl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-015);
Cyclopropanecarboxylic acid (5-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-amide (PP-016);
3-Cyclohexyl-N-[5-(4-hydroxy-3,5-dimethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-propionamide (PP-017);
Cyclohexanecarboxylic acid (5-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-amide (PP-018);
Furan-2-carboxylic acid [5-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amide (PP-019);
Furan-2-carboxylic acid [5-(4-hydroxy-3,5-dimethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amide (PP-020);
3-Methoxy-N-(5-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-propionamide (PP-021);
4-[2-(Cyclopropanecarbonyl-amino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl]-N-(2-hydroxy-ethyl)-benzamide (PP-022);
Cyclopropanecarboxylic acid (5-furan-3-yl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-amide (PP-023);
N-[5-(3-Amino-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-3-pyridin-3-yl-propionamide (PP-024);
N-[6-(5-Methanesulfonyl-pyridin-3-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-acetamide (PP-025); and
N-[6-(3,4-Dimethoxy-phenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-acetamide (PP-026).

### Claim 36 (depends on 35)

A compound according to claim 35, wherein:
—X═ is independently —CR6═;
—R5 is independently —R5A;
—R6 is independently —R6A;
—R7 is independently —R7A;
—R8 is independently —R8A;
—W is independently —WA; and
—WA is independently —C(═O)RWA2.

### Claim 37 (depends on 36)

A compound according to claim 36, wherein —R6A, if present, is independently —H.

### Claim 38 (depends on 36)

A compound according to claim 36, wherein —R6A, if present, is independently -Q6A.

### Claim 39 (depends on 36)

A compound according to claim 36, wherein —R7A is independently —H.

### Claim 40 (depends on 36)

A compound according to claim 36, wherein —R7A is independently -Q7A.

### Claim 41 (depends on 36)

A compound according to claim 36, wherein —R8A is independently —H.

### Claim 42 (depends on 36)

A compound according to claim 36, wherein —R8A is independently -Q8A.

### Claim at position 26

43-47. (canceled)

### Claim 48 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently:
—R1A1, —R1A4, —R1A6, —R1A7, —R1A8,
-L1A-R1A4, -L1A-R1A6, -L1A-R1A7, or -L1A-R1A8.

### Claim 49 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently —R1A1, —R1A4, —R1A6, -L1A-R1A4, or -L1A-R1A6.

### Claim 50 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently —R1A1, —R1A4, or —R1A6.

### Claim 51 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently —R1A1.

### Claim 52 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently —R1A4, —R1A6, -L1A-R1A4, or -L1A-R1A6.

### Claim 53 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently —R1A4 or —R1A6.

### Claim 54 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently —R1A4.

### Claim 55 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently —R1A6.

### Claim 56 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently -L1A-R1A4, or -L1A-R1A6.

### Claim 57 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently -L1A-R1A4.

### Claim 58 (depends on 36)

A compound according to claim 36, wherein —RWA2, if present, is independently -L1A-R1A6.

### Claim at position 38

59-68. (canceled)

### Claim 69 (depends on 36)

A compound according to claim 36, wherein each -L1A-, if present, is independently —CH2—.

### Claim 70 (depends on 36)

A compound according to claim 36, wherein each —R1A1, if present, is independently saturated aliphatic C1-3alkyl.

### Claim 71 (depends on 36)

A compound according to claim 36, wherein each —R1A4, if present, is independently saturated C3-5cycloalkyl.

### Claim 72 (depends on 36)

A compound according to claim 36, wherein each —R1A4, if present, is independently saturated C3cycloalkyl.

### Claim 73 (depends on 36)

A compound according to claim 36, wherein each —R1A6, if present, is independently azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, azepinyl, diazepinyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, and is optionally substituted.

### Claim 74

(canceled)

### Claim 75 (depends on 36)

A compound according to claim 36, wherein each —R1A7, if present, is independently phenyl or naphthyl, and is optionally substituted.

### Claim at position 46

76-81. (canceled)

### Claim 82 (depends on 36)

A compound according to claim 36, wherein each —R1A8, if present, is independently C5-6heteroaryl, and is optionally substituted.

### Claim 83 (depends on 36)

A compound according to claim 36, wherein each —R1A8, if present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, or pyridazinyl, and is optionally substituted.

### Claim at position 49

84-123. (canceled)

### Claim 124 (depends on 36)

A compound according to claim 36, wherein -Q5A, if present, is independently:
—R2A1, —R2A2, —R2A3, —R2A4, —R2A5, —R2A6, —R2A7, —R2A8,
-L2A-R2A4, -L2A-R2A5, -L2A-R2A6, -L2A-R2A7, -L2A-R1A8,
—CF3, —OCF3,
-L2C-OH, —O-L2C-OH,
-L2C-OR2C1, —O-L2C-OR2C1,
—O—R2D4, —O—R2D6, —O—R2D7, —O—R2D8,
—O-L2D-R2D4, —O-L2D-R2D6, —O-L2DR2D7, —O-L2D-R2D8,
—SR2C1,
—NHR2C1, —NR2C12, —NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
—O-L2C-NH2, —O-L2C-NHR2C1, —O-L2C-NR2C12, —O-L2C-NR2C2R2C3,
—C(═O)OR2C1,
—C(═O)R2C1,
—C(═O)NH2, —C(═O)NHR2C1, —C(═O)NR2C12, —C(═O)NR2C2R2C3,
—NHC(═O)R2C1, —NR2C1C(═O)R2C1,
—NHC(═O)NH2, —NHC(═O)NHR2C1,
—NHC(═O)NR2C12, —NHC(═O)NR2C2R2C3,
—NR2C1C(═O)NH2, —NR2C1C(═O)NHR2C1,
—NR2C1C(═O)NR2C12, —NR2C1C(═O)NR2C2R2C3,
—NHS(═O)2R2C1, —NR1C1S(═O)2R2C1,
—S(═O)2NH2, —S(═O)2NHR2C1, —S(═O)2NR2C12, —S(═O)2NR2C2R2C3,
—S(═O)R2C1, or —S(═O)2R2C1.

### Claim at position 51

125-127. (canceled)

### Claim 128 (depends on 36)

A compound according to claim 36, wherein -Q5A, if present, is independently —R2A7 or —R2A8.

### Claim at position 53

129-147. (canceled)

### Claim 148 (depends on 36)

A compound according to claim 36, wherein each —R2A7, if present, is independently phenyl or naphthyl, and is optionally substituted.

### Claim 149 (depends on 2)

A compound according to claim 2, wherein each —R2A7, if present, is independently phenyl or naphthyl, and is optionally substituted.

### Claim at position 56

150-152. (canceled)

### Claim 153 (depends on 36)

A compound according to claim 36, wherein each —R2A8, if present, is independently C5-6heteroaryl, and is optionally substituted.

### Claim 154 (depends on 2)

A compound according to claim 2, wherein each —R2A8, if present, is independently C5-6heteroaryl, and is optionally substituted.

### Claim at position 59

155-229. (canceled)
